ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by co-inventor and co-owner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use.

CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods.


Eric Rhodes


Eric serves as the CEO of ERS Genomics. He recently joined ERS from Horizon Discovery where he held the role of Senior Vice President of R&D and Chief Technology Officer and was responsible for commercializing Horizon's genome editing technologies as well as overseeing research and development. Over the course of his career he has held various positions focused on gene editing technologies including the positions of Director Business Development at Sigma-Aldrich and Vice President Business Development & Alliance Management at Sangamo Biosciences where he was responsible for commercializing gene-editing technologies and executed licensing deals with more than 25 major biotechnology and pharmaceutical companies. Eric holds a degree in microbiology and immunology from the University of California, Berkeley.



Business Development

Trevor brings over a decade of experience in the field of genome editing and its application. He has operated in key roles in R&D, business development, marketing and alliance management for early stage development of genome editing technologies at leading companies in the field, including Sangamo Biosciences, CRISPR Therapeutics and Sigma-Aldrich. Trevor received his D.Phil. in Biochemistry from the University of Waikato, New Zealand, followed by post-doctoral studies at University of Cambridge, UK, and the National Institutes of Health, USA.


Dan Carey


Dan brings over 20 years of experience in business development and licensing, mostly at therapeutic focused biotech companies.  Among these, he led the licensing efforts for clinical stage products at WEX Pharmaceuticals in Vancouver, Canada.  As head of the Business Development group at Inex Pharmaceuticals in Vancouver, Canada he was responsible for licensing preclinical and clinical stage therapeutic products and drug delivery technologies.  Prior to this, he negotiated research collaboration and in-license agreements at Cambridge, Massachusetts based Genetics Institute, Inc.  He received his bachelor’s degree in Biochemical Sciences from Harvard.

Dr. Emmanuelle Charpentier

Scientific Advisor and Co-Founder

Dr. Emmanuelle Charpentier is Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and Honorary Professor at Humboldt University, Berlin, Germany. Prior to joining Max Planck, Emmanuelle held an Alexander von Humboldt professorship at the Helmholtz Centre for Infection Research and Hannover Medical School, Germany. For many years, she led research groups at the Laboratory for Molecular Infection Medicine at Umeå University in Sweden and at the Max F. Perutz Laboratories at the University of Vienna in Austria. Her seminal research unveiled the key mechanisms of the CRISPR-Cas9 technology, laying the foundation for the use of CRISPR-Cas9 as a highly versatile and precise gene editing tool.

Emmanuelle studied biochemistry, microbiology and genetics at the University Pierre-and-Marie-Curie in Paris, France where she received her Ph.D. in microbiology for her research performed at the Pasteur Institute. She spent several years working in the U.S., where she held research associate positions at the Rockefeller University, New York University Langone Medical Center, the Skirball Institute of Biomolecular Medicine and St. Jude Children’s Research Hospital.

Emmanuelle’s work has been recognized by numerous awards including the Breakthrough Prize in Life Sciences, the Kavli Prize in Nanoscience, the Japan Prize, the Carus Medal awarded by the Leopoldina German Academy of Sciences, the Gruber Prize in Genetics, the Princess of Asturias Award for Technical and Scientific Research, the Louis Jeantet Prize for Medicine, the Ernst Jung Prize for Medicine, the Göran Gustafsson Prize awarded by the Royal Swedish Academy of Sciences, Le Prix Jean-Pierre Lecocq from the French Academy of Sciences, the L’Oréal Unesco for Women in Science Award 2016, the 2015 Otto Warburg Medal, the Umeå University EC Jubilee Award 2015 (named for her) and the 2015 Hansen Family Award. Emmanuelle was also recognized by TIME as one of The Most Influential People in 2015.

For press inquiries about Emmanuelle click here.


Shaun Foy

Chairman of the Board and Co-Founder

Shaun is one of our co-founders and serves as our Chairman of the Board. He brings almost 20 years of experience in emerging healthcare companies as an entrepreneur, investor and advisor. Previously, Shaun served as CFO and a member of the board of directors of CRISPR Therapeutics, a company that he co-founded in 2013 that is focused on the therapeutic applications of the CRISPR-Cas9 technology. Prior to that he was a partner and one of the founding team members of Nomura Phase4 Ventures, a London-based venture capital group investing in emerging healthcare companies where he gained particular experience investing in cell and gene therapy companies. Prior to that, he worked with Nomura International’s healthcare corporate finance group advising emerging healthcare companies on M&A and capital raisings.

Shaun is a CFA® charterholder and holds an MSc in cell biology and immunology from the University of British Columbia in Canada.